Adapt Age Record For Free

Trial data showed that significantly more Vyvgart-treated patients with anti-AChR antibodies had meaningful improvements in MG-ADL scores during the first treatment cycle compared with those on a placebo (67.7% vs. 29.7%), meeting the trial's main goal.

Vyvgart (efgartigimod) was FDA-approved in December 2021 to treat generalized myasthenia gravis (MG) in people who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart can improve MG symptoms, including trouble talking, swallowing, and breathing.

Efgartigimod induced a rapid reduction of total IgG levels (up to 63.7% mean change from baseline), which was associated with clinically relevant increases in platelet counts (46% patients on efgartigimod vs 25% on placebo achieved a platelet count of ?50 × 109 /L on at least two occasions, and 38% vs 0% achieved ?50 × ...

ARGX-113 is a proprietary antibody Fc-fragment based on argenx' ABDEG? technology. ABDEG? mutations dramatically increase the Fc/FcRn binding both at neutral and acidic pH.

Studies have shown that efgartigimod can bind and block FcRn, reducing IgG antibodies. Efgartigimod, an IgG1 Fc fragment, is designed for increased affinity for FcRn7. It competes with IgG to occupy FcRn and reduce overall IgG recycling7.

Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer.

In the study, 65 people who were anti-AChR antibody positive were treated with Vyvgart. Of these people, 68% experienced a significant improvement in their symptoms for at least 4 weeks. Of the 64 people treated with placebo who were anti-AChR antibody positive, 30% had this same response.